Valuation: Veru Inc.

Market Cap 44.16M 37.88M 35.37M 32.45M 61.03M 4.22B 62.03M 417M 163M 2.12B 166M 162M 7B P/E 2026 *
-2.55x
P/E 2027 * -2.63x
Enterprise Value 44.16M 37.88M 35.37M 32.45M 61.03M 4.22B 62.03M 417M 163M 2.12B 166M 162M 7B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.63%
Yield 2026 *
-
Yield 2027 * -
1 day+0.58%
1 week-4.75%
Current month+16.51%
1 month+13.47%
3 months+23.69%
6 months+4.82%
Current year+21.96%
1 week 2.54
Extreme 2.54
2.76
1 month 2.16
Extreme 2.16
2.89
Current year 2.05
Extreme 2.05
7.33
1 year 2.05
Extreme 2.05
7.33
3 years 2.05
Extreme 2.05
19.2
5 years 2.05
Extreme 2.05
245.5
10 years 2.05
Extreme 2.05
245.7
Manager TitleAgeSince
Chief Executive Officer 65 31/10/2016
Director of Finance/CFO 67 01/01/2013
Chief Tech/Sci/R&D Officer 64 01/04/2018
Director TitleAgeSince
Chairman 65 01/03/2018
Director/Board Member 68 01/10/2016
Director/Board Member 68 01/03/2018
Date Insider Type Main position Quantity % Market Cap.
8/13/26 A Buy

Chief Technology Officer

1,800 0.0112%
12/5/25 A Free

Chief Executive Officer

100,000 0.6227%
12/5/25 A Free

Director

4,000 0.0249%
Change 5-day change 1-year change 3-year change Capi.($)
+0.58%-4.75%-19.45%-75.61% 44.16M
-1.90%+2.37%+69.11%+110.88% 73.45B
+0.87%+15.32%+56.99%+92.41% 62.99B
+0.44%-2.59%+1.29%+485.68% 28.05B
-1.40%+4.18%+54.52%+19.60% 25.42B
+20.04%+19.36%-0.64%-5.82% 23.3B
+2.28%+5.65%+42.00%-13.75% 19.45B
0.00%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+17.17%+534.55% 16.53B
+2.42%+7.96%+44.96%+154.52% 13.16B
Average +1.97%+1.75%+50.99%+172.63% 28.06B
Weighted average by Cap. +1.33%+4.38%+57.73%+164.85%

Financials

2026 *2027 *
Net sales - -
Net income -25.1M -21.53M -20.1M -18.45M -34.69M -2.4B -35.26M -237M -92.9M -1.2B -94.25M -92.19M -3.98B -37.1M -31.82M -29.72M -27.26M -51.27M -3.55B -52.11M -351M -137M -1.78B -139M -136M -5.88B
Net Debt - -
Logo Veru Inc.
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Employees
20
Date Price Change Volume
19/08/26 $2.610 +0.77% 84,689
18/08/26 $2.590 -1.52% 119,137
17/08/26 $2.630 -3.66% 127,169
14/08/26 $2.730 +1.11% 159,095
13/08/26 $2.700 -1.46% 182,150
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.590USD
Average target price
24.50USD
Spread / Average Target
+845.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VERU Stock